Payment overview · 2025
General Payments
$784.32
47 reported records · 11 companies
Healthcare provider profile · identity verified
Maresa E Muhlethaler, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HOPKINSVILLE, KY · NPI 1952629792
Verified facts
What the public records show
CMS Open Payments records show Maresa E Muhlethaler, NP-C received $784.32 in general payments during 2025 across 47 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $147.74 | 18.8% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $124.01 | 15.8% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $82.87 | 10.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $81.61 | 10.4% | 12 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $75.87 | 9.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.65 | 8.6% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $60.11 | 7.7% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.47 | 7.3% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $54.52 | 7.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.47 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.00 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $784.32 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $147.74 | 18 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.01 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $82.87 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $81.61 | 12 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $75.87 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $67.65 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $60.11 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $57.47 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $54.52 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 199 | 39 |
| Omeprazole | Omeprazole | 188 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 160 | 39 |
| Gabapentin | Gabapentin | 149 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 138 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 131 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 32 |
| Lisinopril | Lisinopril | 123 | 32 |
| Ozempic | Semaglutide | 98 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 25 |
| Meloxicam | Meloxicam | 90 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 16 |
| Trazodone Hcl | Trazodone Hcl | 84 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 14 |
| Metformin Hcl | Metformin Hcl | 82 | 18 |
| Furosemide | Furosemide | 78 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 33 |
| Simvastatin | Simvastatin | 76 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 70 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | 11 |
| Methylprednisolone | Methylprednisolone | 57 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 55 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Allopurinol | Allopurinol | 52 | suppressed |
| Alprazolam | Alprazolam | 52 | suppressed |
| Carvedilol | Carvedilol | 52 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 12 |
| Azithromycin | Azithromycin | 46 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | suppressed |
| Ezetimibe | Ezetimibe | 46 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 42 | 11 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | 14 |
| Prednisone | Prednisone | 34 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Ibu | Ibuprofen | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Ondansetron Odt | Ondansetron | 20 | 11 |
| Eliquis | Apixaban | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Glimepiride | Glimepiride | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Lorazepam | Lorazepam | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tri-Mili | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $784.32 · 47 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Auvelity, BREZTRI, CAPLYTA, DUPIXENT, EVENITY, FANAPT, PROLIA, REXULTI, Senza, VOQUEZNA, VRAYLAR, Veozah | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error